These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

474 related items for PubMed ID: 15301726

  • 21. Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90.
    Le Brazidec JY, Kamal A, Busch D, Thao L, Zhang L, Timony G, Grecko R, Trent K, Lough R, Salazar T, Khan S, Burrows F, Boehm MF.
    J Med Chem; 2004 Jul 15; 47(15):3865-73. PubMed ID: 15239664
    [Abstract] [Full Text] [Related]

  • 22. The Hsp90 chaperone complex as a novel target for cancer therapy.
    Goetz MP, Toft DO, Ames MM, Erlichman C.
    Ann Oncol; 2003 Aug 15; 14(8):1169-76. PubMed ID: 12881371
    [Abstract] [Full Text] [Related]

  • 23. Geldanamycin and its anti-cancer activities.
    Fukuyo Y, Hunt CR, Horikoshi N.
    Cancer Lett; 2010 Apr 01; 290(1):24-35. PubMed ID: 19850405
    [Abstract] [Full Text] [Related]

  • 24. HSP90 as a new therapeutic target for cancer therapy: the story unfolds.
    Maloney A, Workman P.
    Expert Opin Biol Ther; 2002 Jan 01; 2(1):3-24. PubMed ID: 11772336
    [Abstract] [Full Text] [Related]

  • 25. Retaspimycin hydrochloride (IPI-504): a novel heat shock protein inhibitor as an anticancer agent.
    Hanson BE, Vesole DH.
    Expert Opin Investig Drugs; 2009 Sep 01; 18(9):1375-83. PubMed ID: 19642950
    [Abstract] [Full Text] [Related]

  • 26. Alleviating neurodegeneration by an anticancer agent: an Hsp90 inhibitor (17-AAG).
    Waza M, Adachi H, Katsuno M, Minamiyama M, Tanaka F, Sobue G.
    Ann N Y Acad Sci; 2006 Nov 01; 1086():21-34. PubMed ID: 17185503
    [Abstract] [Full Text] [Related]

  • 27. Heat shock protein 90 inhibition by 17-allylamino-17- demethoxygeldanamycin: a novel therapeutic approach for treating hormone-refractory prostate cancer.
    Neckers L.
    Clin Cancer Res; 2002 May 01; 8(5):962-6. PubMed ID: 12006507
    [No Abstract] [Full Text] [Related]

  • 28. 17-AAG, an Hsp90 inhibitor, causes kinetochore defects: a novel mechanism by which 17-AAG inhibits cell proliferation.
    Niikura Y, Ohta S, Vandenbeldt KJ, Abdulle R, McEwen BF, Kitagawa K.
    Oncogene; 2006 Jul 13; 25(30):4133-46. PubMed ID: 16501598
    [Abstract] [Full Text] [Related]

  • 29. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
    Kasibhatla SR, Hong K, Biamonte MA, Busch DJ, Karjian PL, Sensintaffar JL, Kamal A, Lough RE, Brekken J, Lundgren K, Grecko R, Timony GA, Ran Y, Mansfield R, Fritz LC, Ulm E, Burrows FJ, Boehm MF.
    J Med Chem; 2007 Jun 14; 50(12):2767-78. PubMed ID: 17488003
    [Abstract] [Full Text] [Related]

  • 30. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.
    Sydor JR, Normant E, Pien CS, Porter JR, Ge J, Grenier L, Pak RH, Ali JA, Dembski MS, Hudak J, Patterson J, Penders C, Pink M, Read MA, Sang J, Woodward C, Zhang Y, Grayzel DS, Wright J, Barrett JA, Palombella VJ, Adams J, Tong JK.
    Proc Natl Acad Sci U S A; 2006 Nov 14; 103(46):17408-13. PubMed ID: 17090671
    [Abstract] [Full Text] [Related]

  • 31. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin.
    Guo F, Rocha K, Bali P, Pranpat M, Fiskus W, Boyapalle S, Kumaraswamy S, Balasis M, Greedy B, Armitage ES, Lawrence N, Bhalla K.
    Cancer Res; 2005 Nov 15; 65(22):10536-44. PubMed ID: 16288046
    [Abstract] [Full Text] [Related]

  • 32. Mechanistic studies on Hsp90 inhibition by ansamycin derivatives.
    Onuoha SC, Mukund SR, Coulstock ET, Sengerovà B, Shaw J, McLaughlin SH, Jackson SE.
    J Mol Biol; 2007 Sep 14; 372(2):287-97. PubMed ID: 17662999
    [Abstract] [Full Text] [Related]

  • 33. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
    Schwock J, Pham NA, Cao MP, Hedley DW.
    Cancer Chemother Pharmacol; 2008 Apr 14; 61(4):669-81. PubMed ID: 17579866
    [Abstract] [Full Text] [Related]

  • 34. Hsp90: the vulnerable chaperone.
    Chiosis G, Vilenchik M, Kim J, Solit D.
    Drug Discov Today; 2004 Oct 15; 9(20):881-8. PubMed ID: 15475321
    [Abstract] [Full Text] [Related]

  • 35. 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration.
    Waza M, Adachi H, Katsuno M, Minamiyama M, Sang C, Tanaka F, Inukai A, Doyu M, Sobue G.
    Nat Med; 2005 Oct 15; 11(10):1088-95. PubMed ID: 16155577
    [Abstract] [Full Text] [Related]

  • 36. Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis.
    Sanderson S, Valenti M, Gowan S, Patterson L, Ahmad Z, Workman P, Eccles SA.
    Mol Cancer Ther; 2006 Mar 15; 5(3):522-32. PubMed ID: 16546966
    [Abstract] [Full Text] [Related]

  • 37. [Hsp90: how a chaperone becomes a pharmacological target].
    Jacquemin-Sablon A.
    Bull Cancer; 2003 Nov 15; 90(11):935-6. PubMed ID: 14706894
    [No Abstract] [Full Text] [Related]

  • 38. Overview: translating Hsp90 biology into Hsp90 drugs.
    Workman P.
    Curr Cancer Drug Targets; 2003 Oct 15; 3(5):297-300. PubMed ID: 14529382
    [Abstract] [Full Text] [Related]

  • 39. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
    Kim T, Keum G, Pae AN.
    Expert Opin Ther Pat; 2013 Aug 15; 23(8):919-43. PubMed ID: 23641970
    [Abstract] [Full Text] [Related]

  • 40. [Molecular chaperone HSP90 as a novel target for cancer chemotherapy].
    Miyata Y.
    Nihon Yakurigaku Zasshi; 2003 Jan 15; 121(1):33-42. PubMed ID: 12617036
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.